Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Raymond Snyder"'
Autor:
Arthur Hsu, Graham R. Taylor, Renata Marquis, Andrew W. Roberts, Andrew Fellowes, Stephen B. Fox, Ben Tran, Ken Doig, Belinda Lee, Paul A. James, Anne Hamilton, Jayesh Desai, Raymond Snyder, Jennifer Mooi, Paul G Ekert, Grant A. McArthur, Dishan Herath, Paul Waring, Clara Gaff
Publikováno v:
Internal Medicine Journal. 48:786-794
BACKGROUND: Technology has progressed from single gene panel to large-scale genomic sequencing. This is raising expectations from clinicians and patients alike. The utility and performance of this technology in a clinical setting needs to be evaluate
Publikováno v:
Journal of the National Comprehensive Cancer Network. 15:1104-1110
Background: A low proportion of adults with cancer are recruited to clinical trials. Cancer Council Victoria provides funding to clinical trial sites through its statewide Cancer Trials Management Scheme (CTMS). Historically, there appeared to be a r
Autor:
Fionn Woodcock, Brett Doble, Stephen B. Fox, Ian Collins, Theresa Hayes, Madhu Singh, Gary Richardson, Lara Lipton, So-Young Moon, Mark Lucas, Andrew Fellowes, Huiling Xu, Heather Thorne, John J. McNeil, Paula Lorgelly, David M. Thomas, Paul A. James, Tomas John, Gail Risbridger, Gavin Wright, Raymond Snyder
Publikováno v:
Medical Decision Making. 38(8)
Objectives: To assess the external validity of mapping algorithms for predicting EQ-5D-3L utility values from EORTC QLQ-C30 responses not previously validated and to assess whether statistical models not previously applied are better suited for mappi
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 24(4)
Background Anthracycline-based chemotherapy is used in many malignancies. Current recommendations by several groups suggest cardiac monitoring prior to and during anthracycline therapy. We aim to review the usefulness of baseline cardiac screening fo
Autor:
A. Goldhirsch, Richard D. Gelber, S. Aebi, Edda Simoncini, Diana Crivellari, Barry A. Gusterson, Danielle Braun, Per Karlsson, Zhuoxin Sun, Meredith M. Regan, Manuela Rabaglio, Karen N. Price, J. Lindtner, M. Castiglione-Gertsch, Alan S. Coates, Raymond Snyder, Giuseppe Viale
Publikováno v:
Aebi, S; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Lindtner, J; Snyder, R; Karlsson, P; Simoncini, E; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A (2011). Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Annals of oncology, 22(9), pp. 1981-7. Oxford: Oxford University Press 10.1093/annonc/mdq754
Background: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-positive lymph node-negative breast cancer is being reassessed. Patients and methods: After stratification by ER status, 1669 postmenopausal patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf82f7af05b736383c5103e291b5c758
http://doc.rero.ch/record/304488/files/mdq754.pdf
http://doc.rero.ch/record/304488/files/mdq754.pdf
Autor:
Michelle White, Ken Pittman, Maree Colosimo, Sue Chua, Prudence A. Francis, Nicholas Wilcken, Raymond Snyder, Richard De Boer, Jane Beith, Michael D. Green, Jacquie Chirgwin, Paul N. Mainwaring, Nicholas Zdenkowski, Richard Bell
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 10:1-14
Aim We aimed to systematically review and summarize data from the available clinical trials that examined the treatment of HER2-positive metastatic breast cancer. Methods We reviewed phase 2 and 3 studies in which an anti-HER2 agent was used in one o
Autor:
Say Liang Ng, Genni M Newnham, W. I. Burns, Sue-Anne McLachlan, Raymond Snyder, Anthony Dowling, Danny Liew
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 8:172-179
Aim: To examine the relationship between changes in serum carcinoembryonic antigen (CEA) levels and survival during oxaliplatin-based chemotherapy for metastatic colorectal cancer (mCRC). Methods: A retrospective review of 142 patients with mCRC who
Autor:
Michael Michael, Prudence A. Francis, Shom Goel, J. Dewar, Jacquie Chirgwin, Raymond Snyder, Bogda Koczwara, Linda Mileshkin, Robin Stuart-Harris
Publikováno v:
The Breast. 20:101-110
The management of HER2-positive metastatic breast cancer, a disease renowned for its aggressive natural history, has been revolutionized by the introduction of trastuzumab. Indeed, outcomes for patients with HER2-positive advanced breast cancer are n
Autor:
R. D. Gelber, Zhuoxin Sun, A. Goldhirsch, Diana Crivellari, Fatima Cardoso, Raymond Snyder, Meredith M. Regan, Otto Metzger, A. S. Coates, G. Viale
Publikováno v:
Cancer Research. 70:P5-13
Background: To explore the patterns of breast cancer (BC) relapse according to BC subtypes in a lower risk (lymph node (LN)-negative) population we classified pts from two trials according to a molecular classification using IHC surrogates. IBCSG Tri
Autor:
Richard De Boer, Nicole McCarthy, Nicholas Wilcken, Frances M. Boyle, Paul Craft, Arlene Chan, Paul N. Mainwaring, Raymond Snyder
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 5:4-16
Primary and acquired resistance to trastuzumab pose a therapeutic challenge when treating patients with HER2 (erbB-2)-positive locally advanced or metastatic breast cancer (MBC). The recent introduction of lapatinib (Tykerb/Tyverb, GlaxoSmithKline, B